Innovative Gene-Edited Immune Cells Pave the Way for Universal 'Off-the-Shelf' Cancer Treatments
Scientists have developed a universal, off-the-shelf CAR-T cell therapy using gene editing to enhance immune evasion, promising faster and more accessible cancer treatment options.
Researchers at Peking University have made a significant breakthrough in cancer immunotherapy by developing a universal, ready-to-use treatment option. Led by Professor Wei Wensheng and in collaboration with the PLA General Hospital and biotech firm EdiGene Inc., the team has engineered a form of CAR-T cell therapy that can be administered to any patient without the need for custom preparation. This groundbreaking approach could dramatically increase accessibility and reduce costs associated with traditional CAR-T therapies.
CAR-T therapy, which involves reprogramming a patient's own immune cells to target cancer, has shown remarkable success against certain blood cancers like leukemia and lymphoma. However, its application has been limited due to the lengthy, expensive, and personalized manufacturing process, as well as challenges related to immune rejection when using donor cells.
To overcome these obstacles, the scientists focused on modifying donor CAR-T cells by removing a specific gene that acts as a marker for immune rejection. They then applied a glycan shielding technique, which adds a protective coating to the cells, allowing them to evade the host’s immune defenses. This 'armor' ensures the donor cells can survive longer within the patient's body.
Laboratory tests and initial patient trials demonstrated that these gene-edited, 'shielded' CAR-T cells maintain comparable cancer-killing effectiveness to traditional CAR-T cells. Importantly, they exhibited a longer persistence in the body without triggering severe side effects, showcasing their safety and potential as a universal therapy.
This innovative approach signifies a major step toward creating off-the-shelf CAR-T treatments that are quicker to deploy, more affordable, and widely available, offering renewed hope for cancer patients who previously lacked options. If further clinical trials confirm these findings, it could revolutionize cancer immunotherapy by making life-saving treatments accessible to all.
For more details, see the original study published in "Cell": Zeguang Wu et al, Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy, 2025. DOI: 10.1016/j.cell.2025.07.046
Source: https://medicalxpress.com/news/2025-09-gene-immune-cells-universal-shelf.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Home-Based Follow-Up Care Enhances Outcomes for Women and Younger Heart Failure Patients
A new study reveals that in-home follow-up care via mobile health improves outcomes for women and younger heart failure patients, reducing readmission rates and enhancing recovery.
Gut Microbes as a Key to Enhancing Cancer Immunotherapy Response Through Exercise
New research uncovers how exercise reshapes the gut microbiome to produce compounds like formate, enhancing cancer immunotherapy response and improving patient outcomes.
Rise in No/Low Alcohol Beverage Market Driven by Heavy Drinkers
The UK's no/low alcohol drink market is booming, especially among heavy drinkers, raising questions about public health impacts and affordability. Learn more about recent research insights.
Is It Still Worth Getting a Flu Shot in 2025?
Learn why getting a flu shot in 2025 is still highly recommended, even as the season peaks and extends. Protect yourself and those around you by understanding vaccine effectiveness, safety, and timing.